Brief: Procept Biorobotics Receives US FDA Investigational Device Exemption To Investigate Aquablation Therapy For Prostate Cancer
12/09/2023 14:16
Sept 12 (Reuters) - Procept Biorobotics Corp PRCT.O :
* PROCEPT BIOROBOTICS® RECEIVES U.S. FDA INVESTIGATIONAL
DEVICE
EXEMPTION TO INVESTIGATE AQUABLATION® THERAPY FOR PROSTATE
CANCER
* PROCEPT BIOROBOTICS CORP - IDE APPROVAL ALLOWS PROCEPT
BIOROBOTICS TO INITIATE A SINGLE-ARM FEASIBILITY STUDY IN UNITED
STATES
Source text for Eikon: ID:nGNX8PsSX
Further company coverage: PRCT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on PROCEPT BioRobotics
See all newsU.S. STOCKS ON THE MOVE -VF Corp, Biogen, AbbVie
US STOCKS ON THE MOVE-SpaceX, Humana, AbbVie
U.S. STOCKS ON THE MOVE-SpaceX, Humana, Crescent Energy
MedTech growth concerns likely to overshadow Q3 results, Leerink says
Brief: Procept Biorobotics Corporation Enters Third Amendment To Loan And Security Agreement With Cibc